Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02215, USA.
Breast Cancer Res. 2011 Oct 13;13(5):315. doi: 10.1186/bcr2941.
Mutation of p53 occurs in 15 to 20% of all breast cancers, and with higher frequency in estrogen-receptor negative and high-grade tumors. Certain p53 mutations contribute to malignant transformation not only through loss of wild-type p53 but also through a gain of function of specific p53 mutations. How these hotspot mutations turn p53 from a tumor suppressor into an oncogene had until now remained incompletely understood. In an elegant paper published in the July 12 issue of Cancer Cell, Girardini and colleagues show how Pin1-mediated prolyl isomerization, a regulatory mechanism intended by evolution to support p53's function as a guardian of the genome, can go haywire and accelerate malignant transformation when p53 carries a dominant-negative mutation.
p53 基因突变发生于所有乳腺癌的 15%至 20%,且在雌激素受体阴性和高级别肿瘤中更为常见。某些 p53 突变不仅通过野生型 p53 的缺失,还通过特定 p53 突变的获得性功能,促进恶性转化。这些热点突变如何将 p53 从抑癌基因转变为癌基因,至今仍不完全清楚。在 7 月 12 日的《癌细胞》杂志上发表的一篇精彩论文中,Girardini 及其同事展示了 Pin1 介导的脯氨酸异构化(一种进化过程中旨在支持 p53 作为基因组守护者功能的调节机制)如何发生故障,并在 p53 携带显性负突变时加速恶性转化。